Research programme: AQP9 inhibitors - Apoglyx
Latest Information Update: 19 Jul 2016
At a glance
- Originator Lund University
- Developer Apoglyx
- Class Small molecules
- Mechanism of Action AQP9 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Type 2 diabetes mellitus